Imperial College London

Peter Openshaw - Professor of Experimental Medicine

Faculty of MedicineNational Heart & Lung Institute

Senior Consul, Professor of Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3854p.openshaw Website CV

 
 
//

Assistant

 

Ms Gale Lewis +44 (0)20 7594 0944

 
//

Location

 

353Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Jefferies:2020:infdis/jiaa239,
author = {Jefferies, K and Drysdale, SB and Robinson, H and Clutterbuck, EA and Blackwell, L and McGinley, J and Lin, G-L and Galal, U and Nair, H and Aerssens, J and Öner, D and Langedijk, A and Bont, L and Wildenbeest, JG and Martinon-Torres, F and Rodríguez-Tenreiro, Sánchez C and Nadel, S and Openshaw, P and Thwaites, R and Widjojoatmodjo, M and Zhang, L and Nguyen, TL-A and Giaquinto, C and Giordano, G and Baraldi, E and Pollard, AJ and Respiratory, Syncytial Virus Consortium in Europe RESCEU Investigators},
doi = {infdis/jiaa239},
journal = {Journal of Infectious Diseases},
title = {Presumed risk factors and biomarkers for severe respiratory syncytial virus disease and related sequelae: protocol for an observational multicenter, case-control study from the respiratory syncytial virus consortium in Europe (RESCEU).},
url = {http://dx.doi.org/10.1093/infdis/jiaa239},
year = {2020}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Respiratory syncytial virus (RSV) is the leading viral pathogen associated with acute lower respiratory tract infection and hospitalization in children < 5 years of age worldwide. While there are known clinical risk factors for severe RSV infection, the majority of those hospitalized are previously healthy infants. There is consequently an unmet need to identify biomarkers that predict host response, disease severity, and sequelae. The primary objective is to identify biomarkers of severe RSV acute respiratory tract infection (ARTI) in infants. Secondary objectives include establishing biomarkers associated with respiratory sequelae following RSV infection and characterizing the viral load, RSV whole-genome sequencing, host immune response, and transcriptomic, proteomic, metabolomic and epigenetic signatures associated with RSV disease severity. Six hundred thirty infants will be recruited across 3 European countries: the Netherlands, Spain, and the United Kingdom. Participants will be recruited into 2 groups: (1) infants with confirmed RSV ARTI (includes upper and lower respiratory tract infections), 500 without and 50 with comorbidities; and (2) 80 healthy controls. At baseline, participants will have nasopharyngeal, blood, buccal, stool, and urine samples collected, plus complete a questionnaire and 14-day symptom diary. At convalescence (7 weeks ± 1 week post-ARTI), specimen collection will be repeated. Laboratory measures will be correlated with symptom severity scores to identify corresponding biomarkers of disease severity. CLINICAL TRIALS REGISTRATION: NCT03756766.
AU - Jefferies,K
AU - Drysdale,SB
AU - Robinson,H
AU - Clutterbuck,EA
AU - Blackwell,L
AU - McGinley,J
AU - Lin,G-L
AU - Galal,U
AU - Nair,H
AU - Aerssens,J
AU - Öner,D
AU - Langedijk,A
AU - Bont,L
AU - Wildenbeest,JG
AU - Martinon-Torres,F
AU - Rodríguez-Tenreiro,Sánchez C
AU - Nadel,S
AU - Openshaw,P
AU - Thwaites,R
AU - Widjojoatmodjo,M
AU - Zhang,L
AU - Nguyen,TL-A
AU - Giaquinto,C
AU - Giordano,G
AU - Baraldi,E
AU - Pollard,AJ
AU - Respiratory,Syncytial Virus Consortium in Europe RESCEU Investigators
DO - infdis/jiaa239
PY - 2020///
SN - 0022-1899
TI - Presumed risk factors and biomarkers for severe respiratory syncytial virus disease and related sequelae: protocol for an observational multicenter, case-control study from the respiratory syncytial virus consortium in Europe (RESCEU).
T2 - Journal of Infectious Diseases
UR - http://dx.doi.org/10.1093/infdis/jiaa239
UR - https://www.ncbi.nlm.nih.gov/pubmed/32794560
UR - https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa239/5892594
ER -